trending Market Intelligence /marketintelligence/en/news-insights/trending/Lqr1zWUR86wNnpeLHTSumQ2 content esgSubNav
In This List

Seattle Genetics breast cancer drug well-tolerated in phase 1 trial

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Seattle Genetics breast cancer drug well-tolerated in phase 1 trial

Seattle Genetics Inc. said ladiratuzumab vedotin was well-tolerated in an ongoing phase 1 trial with metastatic triple negative breast cancer patients.

The study, conducted in 81 patients who had received prior systemic metastatic therapies, recorded a median progression-free survival of 11 weeks. Meanwhile, the median duration of response was 13.3 weeks.

Seattle Genetics reported a 25% objective response rate and 28% clinical benefit rate for 60 efficacy-evaluable patients.

The side effects in the trial included peripheral neuropathy, neutropenia and anemia.